4.5 Article

Near-infrared photoimmunotherapy (NIR-PIT) on cholangiocarcinoma using a novel catheter device with light emitting diodes

期刊

CANCER SCIENCE
卷 112, 期 2, 页码 828-838

出版社

WILEY
DOI: 10.1111/cas.14780

关键词

catheter; cholangiocarcinoma; light emitting diode; near-infrared photoimmunotherapy

类别

资金

  1. Japanese Foundation for Research and Promotion of Endoscopy (JFE) [19H03593]
  2. Uehara Memorial Foundation
  3. JSPS [20J12988]
  4. Pharmaceutical Society of Japan
  5. AMED [JP19am0101093]
  6. Japan Agency for Medical Research and Development
  7. Hokkaido University
  8. Global Facility Center
  9. Pharma Science Open Unit
  10. MEXT
  11. Grants-in-Aid for Scientific Research [19H03593, 20J12988] Funding Source: KAKEN

向作者/读者索取更多资源

NIR-PIT, using NIR light and antibody-photosensitizer conjugates, effectively treated CCA xenografts in mice with the newly developed catheter, suppressing tumor growth significantly compared to controls. The therapy showed efficacy in EGFR- and HER2-expressing CCA cells, suggesting the potential usefulness of the novel catheter with mounted LEDs for NIR-PIT in CCA treatment.
Near-infrared photoimmunotherapy (NIR-PIT) is a novel therapy for cancers that uses NIR light and antibody-photosensitizer (IR700) conjugates. However, it is difficult to deliver NIR light into the bile duct for cholangiocarcinoma (CCA) from the conventional extracorporeal apparatus. Thus, in this study, we developed a dedicated catheter with light emitting diodes (LEDs) that supersedes conventional external irradiation devices; we investigated the therapeutic effect of NIR-PIT for CCA using the novel catheter. The new catheter was designed to be placed in the bile duct and a temperature sensor was attached to the tip of the catheter to avoid thermal burn. An anti-epidermal growth factor receptor (EGFR) antibody, Panitumumab-IR700 conjugate or anti-human epidermal growth factor receptor type 2 (HER2) antibody, Trastuzumab-IR700 conjugate, was used with EGFR- or HER2-expressing cell lines, respectively. The in vitro efficacy of NIR-PIT was confirmed in cultured cells; the capability of the new catheter for NIR-PIT was then tested in a mouse tumor model. NIR-PIT via the developed catheter treated CCA xenografts in mice. NIR-PIT had an effect in Panitumumab-IR700 conjugate- and Trastuzumab-IR700 conjugate-treated CCA cells that depended on the receptor expression level. Tumor growth was significantly suppressed in mice treated with NIR-PIT using the novel catheter compared with controls (P < .01). NIR-PIT was an effective treatment for EGFR- and HER2-expressing CCA cells, and the novel catheter with mounted LEDs was useful for NIR-PIT of CCA.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据